Coordination gap
The answer is roughly known; the field just hasn't synchronized practice.
Resolves via: Guideline update + dissemination
A Class I nudge to test every adult turns a rarely ordered blood test into routine care — and commits millions of people to a lifelong high-risk label that, for now, buys them harder statin and PCSK9 therapy rather than any drug aimed at Lp(a) itself.
Active since Aug 2025
The debate
7 clinicians quoted on the record
Lp(a) is inherited, causal, and invisible on a standard lipid panel, and a single cheap test reliably finds people whose risk justifies pushing LDL much lower, adding a PCSK9 inhibitor, and screening the family — actions we already know help.
“There are three drugs that specifically lower Lp(a) that are in Phase III testing right now. Everybody's getting excited about them, but we must wait on the results.”
“We can't treat the Lp(a), but we can treat everything else, and that's an important component of why we think it ought to be measured in everybody.”
+ 3 more on this side
Calling universal testing Class I promises that testing everyone makes people healthier, but no trial has shown that an Lp(a)-guided strategy changes outcomes, and the honest answer for most patients with an elevated result today is still "treat your other risks" — which we should be doing anyway.
“There are no trials suggesting that this strategy changes outcomes.”
“A Class I recommendation for universal screening is a claim that testing everyone will lead to actions that make people healthier.”
Where the experts land
5–2 on record
Test everyone now · 5
Wait for a drug that works · 2
“There are three drugs that specifically lower Lp(a) that are in Phase III testing right now. Everybody's getting excited about them, but we must wait on the results.”
Who we found publicly on the record — a snapshot, not a poll of the field. Larger dots are deciders; dashed dots are scan-reported, not yet verified.
Where the field stands
Common ground
Everyone accepts that Lp(a) is a genetic, causal driver of cardiovascular disease that a standard lipid panel misses.
The crux
Whether a result you cannot treat directly justifies testing every adult, or only those in whom it would change management today.
Still unknown
Outcome results from the ongoing trials of drugs that lower Lp(a) directly would largely settle it.
Where do you land?
1 clinician has voted — the split reveals in 9 more.
Where the evidence stands
2026 ACC/AHA guidance made once-in-a-lifetime Lp(a) measurement Class I. Elevated Lp(a) (≥125 nmol/L or 50 mg/dL) is treated as a risk enhancer prompting more aggressive LDL lowering; PCSK9 mAb is Class I in clinical ASCVD with high Lp(a) not at goal. No outcome-proven Lp(a)-lowering drug is yet approved, so the test currently changes intensity of other therapies rather than offering a specific treatment. Testing rates in the U.S. remain ~1%. Some clinicians argue screening without a dedicated therapy is premature; others say missing a causal, genetic risk factor is no longer acceptable.
What's settled
4What's still open
4How this gets settled
Guideline to move
The 2022 ESC guidelines recommend that Lp(a) measurement should be considered at least once in each adult's lifetime.
What tips it: Despite the attention, Lp(a) testing remains infrequent, with one study showing only 1% of the adult population had ever been tested.
Who could settle it
Know an expert who could settle this? Suggest one →
Who this affects
480K–800K
Sources & verification
+ 23 more, each dated and verification-tagged